🔬 Don't miss the latest Business of @MyBioTechniques! This month, we highlight #drugdiscovery #technology partnerships, product launches to support #cellandgenetherapy process development, & #investment in early #disease detection & #precisionmedicine ➡ https://t.co/cpm8BNLxyb

Atelerix today announced a partnership with Cherry Biotech, bringing together proven non-cryogenic biosample preservation technology and advanced organoid models to support growth in the preclinical research and biotech sectors. Read more: https://t.co/ljii43K5EG

.@EpilepsyGtx has raised $33 million in Series A financing to advance its lead gene therapy programme EPY201 through Phase 1/2a clinical trials, with investment from XGEN Venture, the British Business Bank, and a global biopharmaceutical company: https://t.co/wi9aM80kWy

.@EnterpriseThera has published results of its Phase 1 study of ETD001 in the Journal of Cystic Fibrosis, demonstrating that ETD001 is well tolerated in healthy individuals at higher doses than predicted to be therapeutic. https://t.co/s5IOixNJ24

.@valanxbio today announced the formation of its Board of Directors, bringing together industry leaders to support the company's strategic direction as it advances from a research-stage organisation into clinical development and tech commercialisation. https://t.co/US8qbk07wn

This morning, @Lab_Thread_ announced the beta release of its flagship platform, a unified lab software designed to simplify and streamline collaboration across biological research. Read the full press release here: https://t.co/VR6tIsX9G4

This morning, @Atelerix_Ltd announced a new partnership with Labskin, a global leader in laboratory-grown human skin models, to enable the long distance transport of Labskin's advanced in vitro skin models. Read the full press release: https://t.co/3Px8CaRnQv

Today, TRIMTECH Therapeutics announced the appointment of Alison Lawton as Chair of its Board of Directors, bringing substantial expertise in operations and drug development to support TRIMTECH’s accelerated portfolio advancement and next stage of growth➡️ https://t.co/lNwX9847YR

.@SPTLabtech has collaborated with @PacBio to automate PacBio’s Kinnex full-length RNA-seq library prep on SPT’s firefly platform. Validated at Seattle Children’s Genomics & Spatial Biology CoLab, the workflow improves reproducibility and scalability: https://t.co/Eg4L15Arn4

Scottish Brain Sciences today announced that it has opened a new state-of-the-art clinical research centre at #ONEBioHub Aberdeen, a launchpad for start-ups and high potential life science companies looking to rapidly scale and grow. Read more here: https://t.co/e5c4AxMUVy

.@MosaicTXLtd has appointed Dr Stephen Shuttleworth as CSO. With over 30 years of experience, Stephen will support the Company to bring its lead products into the clinic and to build out its pipeline of precision oncology programmes: https://t.co/C3V03qlqTe

Today @ShiftBioscience released new research detailing an improved framework for evaluating benchmark metric calibration in virtual cell models, reinforcing the use of AI virtual cells to accelerate target identification pipelines. Learn more: https://t.co/qYTF2vyrGQ

TRIMTECH Therapeutics today announced the appointment of Dr Mike Hutton to its Scientific Advisory Board. Read the full press release here: https://t.co/hWEHzd0fel

.@SPTLabtech and @AlitheaGenomics have collaborated to provide an automated solution for single-cell transcriptomics. The workflow integrates MERCURIUS FLASH-seq with SPT’s firefly platform, enabling high-throughput, cost efficient single-cell sequencing: https://t.co/4JgPvGvZzC

Today @Optibrium introduced the latest release of its comprehensive molecular design platform, StarDrop 8, integrating collaboration at every stage of the discovery process enabling medicinal chemists to progress more quickly from hit to candidate. https://t.co/etgDf5suQF

Today @nuclera announced expanded access to its eProtein Discovery System for APAC customers through a distributor agreement with Solve Scientific in Australia and New Zealand, providing localised support and expertise to scientists in these regions. https://t.co/JQY3npdsOL

.@proimmune has introduced ProVE SL Self-Loading Class I Monomers, designed to offer unprecedented flexibility, speed and MHC allele-coverage in T cell research, with over 50 alleles available. Read more: https://t.co/eeiOi4LJdW

.@valanxbio has appointed Klaus Orlinger, PhD as CSO. Klaus is an experienced R&D leader with a distinguished track record in pharmaceutical product development joining VALANX from HOOKIPA Pharma, where he served as CSO, VP Research, and Head of Virology: https://t.co/tR5boLvYT0

Today @qureight announced that its Vascul8™ model for pulmonary vascular disorders has been validated in a peer reviewed study, offering the potential to improve treatment options and patient outcomes following surgery. More: https://t.co/h8fmUsfBC9

OMED Health, part of Owlstone Medical, has partnered with @avivaplc to deliver a pilot study, providing 75 Aviva employees with OMED Health Plans. The collaboration will evaluate the impact of the OMED solution on the digestive health of participants: https://t.co/2RMsNWYNPE

Biodesix has expanded its partnership agreement with @BioRad to develop in vitro diagnostic assays for highly sensitive detection of genomic markers focused on oncology applications, utilizing Bio-Rad’s ddPCR™ technology & QX600 platform. More here: https://t.co/YrdihD4xZ5